The FDA is recalling more than 7,000 bottles of the antidepressant duloxetine due to a possible cancer-causing chemical.
PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a ...
Roughly 3 million units were confiscated in the operation as part of a federal crackdown on illegal e-cigarettes.
The U.S. Food and Drug Administration announced Tuesday that it has appointed Dr. Michelle Tarver to head its divis ...
Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...
The Duloxetine Delayed-Release Capsules' voluntary recall began on Oct. 10 after the FDA deemed the medication the ...
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat ...
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...
It has been a very busy year for food recalls in the United States. The U.S. Food and Drug Administration (FDA) and the U.S.
Thousands of bottles of a commonly prescribed antidepressant drug were recalled because they contained a suspected cancer-causing chemical.
PharmaTher (PHRRF) Holdings announced that the U.S. Food and Drug Administration has issued a complete response ... The deficiencies cited in the CRL are classified as MINOR. The FDA requested new and ...